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Abstract 
Two-thirds of patients with multiple myeloma are aged 65 years or more and the prevalence of 
multiple myeloma in elderly patients is expected to rise in the next future. Patients older than 
65 years are usually considered ineligible for transplantation. The introduction of novel agents, such 
as the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor 
bortezomib, combined with conventional chemotherapy, has radically changed the treatment 
paradigm of elderly patients and improved outcome. A sequential approach, consisting of an 
induction regimen associated with a high rate of complete response, followed by 
consolidation/maintenance therapy, induces a profound cytoreduction and delays relapse, thus 
improving survival. Novel agents associated with reduced-intensity autologous transplant showed to 
be safe and effective in fit elderly patients. Patients older than 75 years or vulnerable ones are more 
susceptible to adverse events that negatively affect treatment adherence and outcome. In this 
setting, less toxic regimens and appropriate dose reductions should be adopted. Here we provide an 
overview of novel agent-based treatment strategies for elderly patients with multiple myeloma. 
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1. Introduction 
Multiple myeloma (MM) is a neoplastic plasma-cell disorder characterized by clonal proliferation 
of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood 
or urine, and associated organ dysfunction (Table 1).
1
 Treatment should be immediately started in 
presence of a symptomatic disease, typically characterized by the occurrence of at least one of the 
CRAB symptoms (C: hypercalcemia (> 11.5 mg/dL); R: renal failure (serum 
creatinine > 1.73 mmol/L); A: anemia (hemoglobin < 10 g/dL or > 2 g/dL below the lower limit of 
normal); and B: bone disease (lytic lesions, severe osteopenia or pathologic fractures). In case of 
asymptomatic disease, only close monitoring is recommended. 
  
Table 1. Diagnostic criteria. 
 
 
In the last decades the introduction of autologous stem-cell transplantation (ASCT) and novel 
agents, such as the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, and the 
proteasome inhibitor bortezomib, radically changed the treatment paradigm of MM, extending 
overall survival (OS).
1
 The estimates of 5-year relative survival of patients with MM in the United 
States from 1990–1992 to 2002–2004 showed that this benefit was evident in patients aged less than 
50 years (5-year relative survival: 45–57%) and in those aged 50–59 years (5-year relative survival: 
39–48%), it was less pronounced in those aged 60–69 years (5-year relative survival: 31–36%), and 
it was absent in those older than 70 years of age (5-year relative survival: 27–29%).2 The use of 
more sophisticated imaging techniques, such as computed tomography (CT), magnetic resonance 
imaging (MRI) and positron emission tomography (PET) may help to better define osteolytic 
lesions and identify the disease early. 
Clonal heterogeneity and genomic instability typical of myeloma cells are responsible for clinical 
relapse and refractory disease.
3
 The clinical heterogeneity of MM is due to the coexistence of 
different myeloma clones with various mutation patterns and subsequent biological and clinical 
behaviors. According to a Darwinian evolutionary model, the sequence in which therapies are 
performed may induce different biological responses in the different clones, with the eradication of 
an indolent clone and the growth of a more aggressive one.
4
 This will negatively affect post-relapse 
survival. In the future, a deeper knowledge of the biology of MM cells in the clinical setting should 
guide the choice of therapy to improve outcome and prevent the occurrence of refractory disease.
5
 
At diagnosis, induction therapy has a greater impact on survival duration, in comparison with 
salvage treatment performed at relapse. Novel agents can be combined with conventional 
chemotherapy to create multi-drug regimens that may better overcome clonal heterogeneity of 
myeloma. At diagnosis, the presence of sensitive tumor may increase the chance of deep responses 
of a longer duration and decrease the risk of adverse events with better quality of life and lower 
related health care cost
6
; by contrast, in later phases, the presence of resistant disease significantly 
decreases the proportion of responses and increases the risk of adverse events, negatively affecting 
both quality of life of patients and health care costs.
7
 
The depth of response and its duration are important prognostic factors in MM: the achievement of 
a complete response (CR), with either negative immunofixation or negative minimal residual 
disease (MRD), induces longer progression-free survival (PFS) and overall survival (OS), both in 
young and elderly patients. An analysis performed on 4990 MM patients treated with conventional 
chemotherapy and ASCT showed that patients achieving CR after induction had significantly longer 
PFS and OS compared to those who obtained a partial response (PR) only (59–89 vs. 39–
68 months).
8
 Similarly, attaining a CR proved to be an independent predictor of longer survival in 
elderly patients treated with both conventional chemotherapy and novel agents.
9
 Therefore, 
combination regimens and treatment strategies with high probability of CR should be adopted, 
unless a high risk of serious adverse events suggests a more gentle approach. 
Continuous treatment with novel agents until disease progression or intolerability increased the 
depth of response and extended both PFS and recently OS.
[10], [11], [12], [13] and [14]
 Lenalidomide 
maintenance after melphalan–prednisone–lenalidomide (MPR) induction reduced the risk of 
progression by 66% compared with no maintenance, with no significant increase in toxicity.
14
 This 
advantage was observed regardless of age. Maintenance with bortezomib plus thalidomide (VT) 
after bortezomib-based induction proved to be effective and well tolerated, and extended median 
PFS to 36–39 months.[10], [12], [13], [15], [16] and [17] In a landmark analysis at start of maintenance, in 
patients 65 to 75 years of age, VT maintenance after bortezomib–melphalan–prednisone–




Treatment discontinuation due to therapy-related adverse events is another important factor that 
negatively impacts outcome. Indeed, discontinuations translate into dose-reduction and reduced 
cumulative dose-intensity, affecting efficacy of therapies. This is particularly evident in patients 
older than 75 years, in whom adverse events are a major cause of treatment discontinuation, 
especially with multi-drug regimens.
14
 In this subset of patients, the evaluation of frailty and 
disability is essential to propose tailored therapy in order to reduce treatment discontinuation rate 
and to deliver the highest cumulative dose-intensity.
18
 Three-drug regimens with an acceptable 
toxicity profile are more suitable for fit patients, while 2-drug regimens with a more tolerable 
toxicity profile should be adopted for vulnerable patients to decrease discontinuation, thus allowing 
patients to stay on therapy for a longer period.
19
 
In conclusion, major therapeutic efforts should be concentrated at diagnosis, when the disease is 
sensitive. Regimens associated with high CR rate and continuous therapy should be adopted. 
Treatment toxicity and discontinuation rate should be reduced in order to decrease the frequency of 
adverse events, maximize treatment efficacy and improve outcomes. In unfit patients, a gentler 
approach to minimize adverse events and preserve patient's quality of life is suggested. 
2. Epidemiology 
MM comprises 1% of all cancers and 13% of hematologic malignancies. Median age at diagnosis is 
70 years; 35% of patients are younger than 65 years, 28% aged between 65 and 74 years and 37% 
are older than 75 years.
[20] and [21]
 The incidence and prevalence of MM increase with age: the annual 
age-adjusted incidence rises from < 1/100,000 for subjects younger than 40 years, to > 40/100,000 
for those older than 80 years; the annual prevalence of MM in patients aged 65–74 is approximately 
31/100,000 and rises to 46/100,000 in patients aged older than 75 years. Both the incidence and 
prevalence of MM in elderly patients are expected to grow in the next future due to the increase in 
the life expectancy of the general population and the improved survival times achieved with the 
introduction of novel agents. Although MM is typical of the elderly, these patients are 
underrepresented in clinical trials because comorbidities and frailty often prevent them from being 
enrolled in experimental protocols.
22
 
3. Definition of fit and unfit patients 
The standard age cut-off of 65 years used to evaluate patient's eligibility to ASCT is no longer 
valid, as chronological age and biological age may greatly differ, especially in the geriatric 
population. Aging is associated with modifications in the organ functions that may reduce the 
tolerability of therapy. The presence of comorbidities, frailty and disability should be considered 
when planning treatment as they may negatively impact the outcome of elderly patients. 
Comorbidity is defined by the presence of ≥ 2 concomitant medically diagnosed diseases. Frailty is 
a clinical entity characterized by the presence of ≥ 3 core elements of frailty: weakness, weight loss, 
low physical activity, poor endurance and slow gait speed. Disability is defined by limitations in 
carrying out common daily activities typical of independent living, due to physical or mental 
impairment.
[23] and [24]
 All these factors are associated with an increased risk of therapy-related 
adverse events and consequently a high frequency of treatment discontinuation, affecting efficacy 
and long-term outcomes. Therefore, a careful clinical assessment of a patient's physical condition 
and clinical condition, including the evaluation of organ functions (cardiac, pulmonary, hepatic, 
gastrointestinal and renal) and the presence of frailty (poor endurance, weakness, low physical 
activity) and disability (need for help for household activities and personal care), should be 
routinely performed; this will enable to identify vulnerable elderly patients in whom reduced 
intensity regimens would increase treatment tolerability, reducing early discontinuation and 
optimizing efficacy. Patients without risk factors should receive full-dose treatment, whereas for 
patients with at least one risk factor (age ≥ 75 years, comorbidities, frailty or disability) a reduced 
intensity strategy is recommended.
18
 
4. The grey zone and the role of reduced-intensity transplantation 
Patients older than 65 years of age, or younger with serious comorbidities, are generally considered 
unable to receive high-dose melphalan (200 mg/m
2
; Mel200) followed by ASCT. However, since 
chronological age does not always correspond to biological age, patients older than 65 years in 
excellent clinical condition may be able to tolerate ASCT. For very fit patients, reduced-dose of 
melphalan (100 mg/m
2
; Mel100) followed by ASCT can be an option. Two randomized studies 
comparing reduced-dose of melphalan with the standard MP reported conflicting results. In the first 
study, conducted in patients aged 65 to 70 years, Mel100 followed by ASCT led to longer median 
event-free survival (EFS) (28 months vs. 16.4 months; p < 0.001) and OS (58 months vs. 
37.2 months; p < 0.001) compared with melphalan–prednisone (MP). 25 The second study compared 
MP, MP plus thalidomide (MPT) and Mel100 followed by ASCT in patients aged 65–75 years. 
MPT induced longer PFS and OS in comparison with both MP and Mel100, while no differences 
were observed between MP and Mel100. 
26
 
A German ongoing trial is assessing the role of lenalidomide and low-dose dexamethasone (Rd) as 
induction therapy followed by ASCT in patients 60–75 years of age considered eligible for 
transplantation. An intermediate dose of melphalan (140 mg/m
2
) before ASCT has been adopted. 
Preliminary results confirmed that Rd is a feasible option in elderly patients, and stem cell 
mobilization was successful in 97% of patients.
27
 
Bortezomib administered as induction before transplantation was associated with a high CR rate
28
; 
lenalidomide has shown a great efficacy and lacks neurotoxicity typical of its predecessor 
thalidomide.
29
 These considerations provided the rationale for a phase II study that evaluated safety 
and efficacy of these novel agents in combination with a tandem reduced-intensity ASCT (Mel100), 
in patients aged 65–75 years.30 Induction therapy consisted of bortezomib–doxorubicin–
dexamethasone (PAD) for four 21-day cycles, lenalidomide–prednisone (RP) was administered as 
consolidation for four 28-day cycles, followed by lenalidomide maintenance (R), until progression. 
This sequential approach led to a progressive improvement of response, CR rate increased from 
13% after PAD induction, to 38% after Mel100 and ASCT, to 71% during RP–R 
consolidation/maintenance. After a median follow-up of 36 months, the 3-year time to progression 
(TTP), PFS and OS were 73%, 66% and 85%, respectively. PFS was not significantly different in 
patients younger or older than 70 years (p = 0.16), although it was slightly longer in younger 
patients. The most common grade 3–4 adverse events were thrombocytopenia (17%), neutropenia 
(10%), peripheral neuropathy (16%) and pneumonia (10%); lenalidomide given as 
consolidation/maintenance was well tolerated as it did not cause cumulative or persistent grade 3–4 
neutropenia and thrombocytopenia. Different studies showed that the rate of responses induced by 




The data above suggest that a sequential approach consisting of induction with effective drug 
combinations followed by reduced-dose ASCT and subsequent consolidation/maintenance therapy 
is a valuable therapeutic strategy for very fit elderly patients, or patients younger but not eligible for 
a high-dose melphalan and ASCT. 
5. Active regimens 
5.1. IMiDs-based regimens 
In a randomized, phase III trial including newly diagnosed MM patients ineligible for 
transplantation, thalidomide combined with high-dose dexamethasone (TD) was compared with 
MP.
32
 Although TD yielded to a higher overall response rate (ORR) (68% vs. 50%; p = 0.002) than 
MP, no differences in terms of median time-to-progression (TTP) (21.2 vs. 29.1 months; p = 0.2) 
and PFS (16.7 vs. 20.7 months; p = 0.1) were noted. In patients younger than 75 years, median OS 
was shorter with TD (44.6 vs. 57.9 months; p = 0.14), and this difference was statistically 
significant in patients older than 75 years receiving TD (19.8 vs. 41.3 months; p = 0.071). The 
incidence of early death, occurred within the first year, with TD twice as high as the one reported 
with MP (28% vs. 16%; p = 0.014); in addition, non-myeloma related deaths were higher in the TD 
arm, and infection and cardiovascular events were the main causes. These data show that, despite 
the efficacy benefits observed with TD, this combination is too toxic for elderly patients and the 
lack of clinical benefit was mainly due to high dose dexamethasone. The choice of different steroids 
(e.g. prednisone) and reduced-dose schedules (e.g. low-dose dexamethasone), may increase 
treatment tolerability and efficacy. 
The combination MP had long been the standard of care for patients unsuitable for high-dose 
therapy and transplantation. Six randomized trials explored the efficacy of the addition of 
thalidomide (at different doses, 100–400 mg) to MP in newly diagnosed, transplant ineligible MM 
patients. In two French studies, IFM 99/06 and IFM 01/01, MPT regimen led not only to a higher 
ORR but also to longer PFS and OS than did MP.
[26] and [33]
 Conversely, the Italian trial reported a 
higher ORR and a prolonged PFS in patients treated with thalidomide, but no OS differences were 
noted between MPT and MP.
34
 Similar data were obtained in the Dutch/Belgian study: MPT 
prolonged PFS compared with MP, but no OS advantage was seen.
35
 In two other trials performed 
by the Nordic and Turkish groups, ORR was higher in patients who were given thalidomide, but 




An efficacy meta-analysis of the six MPT trials including 1685 patients was conducted (Table 2).
15
 
Despite the heterogeneity of the trials, both for patient characteristics and thalidomide schedules 
(dose and duration of treatment), the addition of thalidomide to MP significantly prolonged both 
PFS and extended OS by 20% (6.6 months) compared to MP. A safety meta-analysis based on the 
same trials showed that the incidence of grade 3–4 adverse events was higher (at least 75%) during 
the first six months of treatment for both MPT and MP (Table 3).
38
 Grade 3–4 non-hematologic 
adverse events occurred more frequently with MPT than MP (39% vs. 17%), in particular peripheral 
neuropathy (6–23%) and deep-vein-thrombosis (3–12%), and they were significantly increased in 
patients with poor performance status. These results showed the superiority of MPT over the old 
standard of care MP, and MPT is therefore regarded as new standard of care in transplant ineligible 
patients. 
Table 2. Efficacy of selected treatments. 
 
 
 Table 3. Safety of selected treatments. 
 
A phase III trial assessed the role of thalidomide in combination with different alkylating agent and 
steroid than those commonly used, respectively cyclophosphamide and dexamethasone, with an 
attenuated schedule (CTDa).
39
 In this trial, 849 newly diagnosed MM elderly patients were 
randomly allocated to CTDa or MP. Of note, 75% of patients had an advanced stage disease (ISS 
II/III). CTDa resulted in higher ORR (63.8% vs. 32.6 p < 0.0001%), very good partial response 
(VGPR; 16.9% vs. 1.7%) and CR (13.1% vs. 2.4%) than MP. Despite a deeper response, no 
differences were noted in median PFS (13 months vs. 12.4 months, p = 0.1) and OS (33.2 months 
vs. 30.6 months, p = 0.24) between patients treated with CTDa or MP. CTDa induced a higher rate 
of grade 3–4 adverse events, especially peripheral neuropathy, constipation and DVT. However, 
patients with favorable FISH benefited more from CTDa and showed an improved OS. 
Lenalidomide is a potent IMiD derived from thalidomide; this compound showed to be safe and 
effective in relapsed/refractory MM patients, as well as in newly diagnose MM patients.
[40] and [41]
 In 
a phase III trial, lenalidomide plus high-dose dexamethasone (RD) was compared with lenalidomide 
plus low-dose dexamethasone (Rd) in newly diagnosed MM patients, both eligible and ineligible 
for ASCT.
42
 Despite a higher ORR with RD (79% vs. 68.3%, p = 0.008), patients treated with Rd 
had a significantly longer 1-year OS (87% vs. 96%, p < 0.001). The survival benefit associated with 
Rd was particularly evident in patients older than 65 years of age (1-year OS: 83% with RD vs. 
94% with Rd). In a landmark analysis, 3-year OS for patients who continued treatment until 
progression or intolerance was 79%. RD was associated with a worse toxicity profile, with a higher 
incidence of grade 3–4 adverse events, particularly DVT (26% vs. 12%) and infections (16% vs. 
9%). Early deaths were also significantly higher with the high-dose dexamethasone (5% vs. 0.4%, 
p < 0.003). Consequently, discontinuation rate was higher with RD than with Rd (27 % vs. 19%). In 
a subgroup analysis including patients older than 70 years of age, the 3-year OS was 61% with RD 
and 73% with Rd, and the incidence of grade 3–4 non-hematologic adverse events was 78% and 
59%, respectively. Based on these results, Rd regimen can be considered a valid therapeutic option 
for elderly newly diagnosed MM, and low-dose dexamethasone (40 mg weekly) should be preferred 
in this setting. 
5.2. Bortezomib-based regimens 
The international phase III VISTA trial assessed the role of bortezomib in combination with 
melphalan and prednisone (VMP), with the standard MP.
43
 VMP led to higher ORR and CR rate, 
which translated into longer TTP (24 months vs. 16.6 months; p < 0.001) and OS (56.4 vs. 43.1; 
p = 0.0004), with a 31% reduced risk of death. These results were confirmed in different subgroups 
of patients, included patients older than 75 years, but not in those with high-risk cytogenetic profile. 
VMP was more toxic than MP, with grade 3–4 adverse event rate of 91% and a discontinuation rate 
of 34%; the most frequent grade 3–4 toxicities were neutropenia (40%), thrombocytopenia (37%), 
peripheral neuropathy (17%) and infections (10%). When bortezomib schedule was changed from 
twice-weekly (cycles 1 to 4) to once-weekly (cycles 5 to 8), the rate of adverse events decreased in 
the VMP group, with no negative impact on outcome. Therefore, VMP today is considered one of 




In another phase III trial including newly-diagnosed elderly MM patients, VMP was compared with 
bortezomib–dexamethasone (VD) and bortezomib–thalidomide–dexamethasone (VTD).45 In this 
study median age was 72–74.5 years, more than 2/3 of patients had an advanced disease (ISS stage 
II/III) and approximately 50% of them presented with a Charlson comorbidity index ≥ 1. After a 
median follow-up of 21.8 months, the ORR response rate was equivalent in the three regimens 
(69%–80%), and no differences in PFS and OS were noted. Grade 3–4 adverse events and 
discontinuation rate were higher in patients treated with VTD. These data support the use of lower 
doses of standard regimens or a 2-drug combination, rather than a more intense treatment, in very 
elderly patients, or in younger patients with heart, lung, liver, or renal dysfunctions, or in those 
needing help for household care and personal care. 
Promising results came from a phase II study combining bortezomib with cyclophosphamide and 
dexamethasone (VCD) in newly diagnosed MM patients, both eligible and not eligible for 
ASCT.
[46] and [47]
 In the first cohort including 33 patients, twice-weekly bortezomib was 
administered; in the second cohort including other 30 patients, once-weekly bortezomib was given. 
After 4 cycles of induction, the ORR was 90% and the CR/near Cr (nCr) rate was 41%, with no 
differences between the once-weekly and the twice-weekly schedule in terms of response. However, 
the rate of grade 3–4 adverse events was lower with the once-weekly group. 
5.3. Bortezomib plus IMiDs-based regimens 
The proteasome inhibitor bortezomib has been combined with IMiDs, thalidomide and 
lenalidomide, as induction therapy for newly diagnosed MM patients. In the Spanish PETHEMA 
trial, 260 patients older than 65 years or otherwise ineligible for ASCT, were randomized to receive 
6 cycles of either bortezomib–thalidomide–prednisone (VTP) or VMP induction; a gentler approach 
with once-weekly bortezomib was used from cycle 2 of both regimens.
44
 Both VTP and VMP led to 
high ORR rate (81% and 80%, respectively) and CR rate (28% and 20%, respectively). VTP 
regimen was more toxic than VMP, inducing a higher rate of serious adverse events, particularly 
cardiac events, (31% vs. 15%; p = 0.01) and discontinuation rate (17% vs. 12%; p = 0.03). VMP 
was associated with a higher rate of grade 3–4 hematologic adverse events compared to VTP, in 
particular neutropenia (39% vs. 22%; p = 0.008) and thrombocytopenia (27% vs. 12%; p < 0.001). 
The once-weekly schedule of bortezomib adopted after the first cycle, reduced the rate of grade 3–4 
peripheral neuropathy and gastrointestinal symptoms compared with the twice-weekly schedule, 
without affecting efficacy.
43
 Therefore, VMP with a once-weekly schedule of bortezomib should be 
preferred to VTP as induction for elderly MM patients. 
A phase I/II trial evaluated the safety and efficacy of the combination of bortezomib–lenalidomide–
dexamethasone (VRD) in both young and elderly newly diagnosed MM patients.
48
 The first phase 
of this trial established the maximum planned dose of bortezomib (1.3 mg/m
2
), lenalidomide 
(25 mg) and dexamethasone (20 mg cycle 1–4; 10 mg cycle 5–8). Patients who did not proceed to 
ASCT, received eight 3-week cycles of VRD. This regimen proved to be highly effective, leading to 
a PR rate of 100% and a CR/nCR rate of 37%. VRD was also well tolerated: the most frequent 
grade 3–4 adverse events were neutropenia (9%) and thrombocytopenia (6%); in addition, no grade 
4 peripheral neuropathy was reported. After 18 months from start of treatment, PFS was 75% and 
OS was 97%. 
A subsequent phase II trial explored the role of bortezomib–cyclophosphamide–dexamethasone 
(VCD), compared to VRD and VRD plus cyclophosphamide (VDCR) in both transplant eligible 
and ineligible newly diagnosed MM patients.
49
 All regimens were effective: ORR and CR rate were 
75% and 22% with VCD, 85% and 24% with VRD, and 88% and 25% with VDCR. These 
responses translated into similar 1-year PFS (97%, 68%, 83%, respectively) and 1-year OS (100%, 
100%, 92%, respectively). The 4-drug regimen led to higher rate of grade 3–4 adverse events, 
particularly neutropenia, and discontinuation rate, and its efficacy is thus comparable to the 3-drug 
regimens. 
6. Continuous treatment 
Despite the improvement reported with novel agents containing therapies, residual disease is always 
present. Therefore, a continuous treatment to keep residual disease under control is an effective 
strategy. Recently, the international MM015 phase III study assessed the role of lenalidomide given 
as maintenance.
14
 Four-hundred and fifty-nine patients were randomized to receive induction 
therapy consisting of nine 4-week cycles of MPR, followed by either lenalidomide maintenance or 
placebo, or standard MP. Lenalidomide was administered at the dose of 10 mg daily, both at 
induction and during maintenance. The median age at enrollment was 71 years and half of patients 
had advanced disease (ISS III). The ORR was higher with MPR-R and MPR compared with MP 
(77%, 68%, 50%, respectively). MPR-R significantly improved median PFS in comparison with 
MPR and MP (31 months vs. 14 months vs. 13 months; p < 0.001). Of note, MPR-R reduced the 
risk of progression by 51% and 60% compared with MPR and MP, respectively. This advantage 
was more evident in patients younger than 75 years, in whom MPR-R significantly improved PFS 
compared to MPR and MP. In a landmark analysis from start of maintenance, lenalidomide 
maintenance significantly prolonged PFS as compared to placebo, regardless of age (26 months 
with MPR-R vs. 7 months with MPR-placebo, p < 0.001), with a 66% reduced risk of progression. 
The most frequent hematologic grade 4 adverse events were neutropenia (35% with MPR-R, 32% 
with MPR, 8% with MP), and thrombocytopenia (11%, 12%, and 4%, respectively). Infections were 
the most frequent non-hematologic grade 3 adverse events (9% with MPR-R, 13% with MPR, 7% 
with MP), while the rate of deep vein thrombosis (DVT) was low (1%, 4%, and 1%, respectively) 
because thromboprophylaxis with aspirin was used. Maintenance therapy was well tolerated, as the 
rate of new or worsened grade 3–4 adverse events lowered (0 to 6%). 
The role of continuous treatment with bortezomib has been assessed in two different trials. In the 
Spanish PETHEMA trial, patients were randomized to receive bortezomib maintenance (standard 
schedule day 1, 4, 8, 11administerd every 3 months) with either thalidomide (VT) or prednisone 
(VP), after VTP or VMP induction.
17
 After 38 months from the initiation of maintenance, both VT 
and VP increased the CR rate achieved after induction (up to 46% with VT and up to 39% with VP) 
without significantly adding to toxicity (grade 3–4 neutropenia: 1% in the VT arm vs. 0% in the VP 
arm; grade 3–4 peripheral neuropathy: 9% vs. 3%, respectively). PFS was longer with VT 
compared with VP (39 months vs. 32 months, p = 0.1), 5-years OS was slightly prolonged with VT 
(69% vs. 50%, p = 0.1). 
In the Italian study, bortezomib was tested as maintenance in combination with thalidomide (VT), 
after nine 6-week cycles of VMPT induction, and compared with nine 6-week cycles of VMP 
induction followed by placebo. During maintenance, bortezomib was given at the dose of 
1.3 mg/m
2
, every 14 days for up to two years or until disease progression.
[10] and [13]
 After 47 months 
of follow-up, 5-year OS was 59.3% for VMPT–VT and 45.9% for VMP, with a 26% reduced risk 
of death in favor of VMPT–VT. The survival benefit associated with VMPT–VT was more evident 
in patients younger than 75 years (67.8% vs. 49.4%; p = 0.001) and in patients who achieved CR 
after induction (81.4% vs. 48.2%; p = 0.006). On the contrary, no advantage with VMPT–VT was 
observed in patients older than 75 years in comparison with VMP. In a pre-specified landmark 
analysis at the start of maintenance, 4-year OS was 64.6% in the VMPT–VT arm and 49.7% in the 
VMP arm, with a 33% reduced risk of death in favor of VMPT–VT. VT maintenance was well 
tolerated: the incidence of grade 3–4 adverse events was low, with peripheral neuropathy rate of 
7%. No OS differences were noted at relapse, showing that VMPT–VT did not negatively impact 
on efficacy of salvage therapy. When bortezomib schedule was changed from twice- to once-
weekly administration, the incidence of non-hematologic grade 3–4 adverse events decreased from 
51% to 36% (p = 0.003), particularly peripheral neuropathy (from 16% to 3%, p < 0.001).
[10] and [50]
 
This modification did not affect efficacy, as the cumulative delivered dose of bortezomib was 
similar.
50
 Therefore, VMPT–VT with once-weekly bortezomib seems a valid alternative for elderly 
patients, especially for those 65–75 years of age. 
Beside the weekly schedule, the recent use of subcutaneous administration rather than the 
intravenous administration showed to be a feasible and equally effective option.
51
 Therefore, 
subcutaneous bortezomib may be considered for prolonged treatment. 
These data confirm that a sequential approach including maintenance with either lenalidomide alone 
or bortezomib in combination with thalidomide is safe and effective in elderly patients. This 
strategy prolongs PFS with an acceptable toxicity rate, and also extends OS. 
7. Treatment options for fit and unfit patients 
As previously reported, in presence of ≥ 1 risk factor (age ≥ 75 years, presence of comorbidities, 
frailty or disability), dose reductions are recommended (Table 4). In case of grade 3–4 adverse 
events occurring during treatment, therapy should be withheld until the toxicity resolves; therapy 
could then be restarted at the beginning of the next cycle at a lower dose level.
1
 Thalidomide may 
be reduced from 200 mg to 100 mg or even 50 mg per day; lenalidomide from 25 mg to 15–10 mg 
on days 1–21; once weekly administration of bortezomib at the dose of 1.3 mg/m2, or even 
1.0 mg/m
2
, instead of the standard twice-weekly, should be considered; the dose of melphalan may 
be decreased from 0.25 mg to 0.18 mg or even 0.13 mg per kilogram of body weight on days 1–4; 
low-dose schedule dexamethasone (40 mg daily on days 1,8,15,22) should be preferred to the high-





Table 4. Suggested dose adjustments. 
 
The standard of care for elderly patients consists of a 3-drug regimen (VMP, VCD or VRD). In 
patients aged 65–75 years, the 4-drug regimen VMPT can be adopted, as it significantly increased 
the CR rate compared with VMP (38% vs. 24%; p < 0.001).
10
 If an oral treatment is required, 
IMiD-containing regimens are recommended, such as the standard MPT or Rd. Recently, 
maintenance therapy with lenalidomide or VT improved PFS, but longer follow-up is needed to 
detect an OS advantage. Lenalidomide maintenance proved to be highly effective, regardless of age, 
and is a feasible option, especially for its oral administration.
14
 VT maintenance, after bortezomib-




Unfit patients should receive a gentler approach associated with a low rate of adverse events and 
treatment discontinuation. In this setting, 2-drug combinations such as VD and Rd are 
recommended. VD proved to be less toxic and equally effective as VMP and VTD in an elderly and 
frail population.
45
 Similarly, Rd was better tolerated than RD and proved to be even more effective, 
owing to the low-dose schedule of dexamethasone, both in young and elderly patients.
42
 
A phase II trial tested the role of lenalidomide–prednisone (RP) induction, followed by 
consolidation with MPR and subsequent RP maintenance therapy in elderly patients. Median age 
was 75 years and 60% had at least 1 comorbidity.
52
 This strategy led to a significant reduction in the 
rate of grade 4 hematologic adverse events associated with MPR. These results suggest that an 
initial gentler approach with a 2-drug regimen as induction, when toxicity rate is higher, followed 
by a more intense treatment with a 3-drug combination is an effective option for vulnerable elderly 
patients. 
8. Treatment strategy at relapse 
Patients with relapsed MM experience disease progression after achieving maximal response to 
induction treatment, whereas refractory patients either do not respond to therapy or progress within 
60 days from last treatment.
53
 The choice of therapy at relapse should be based on quality and 
duration of response obtained with the previous therapy. A profound cytoreduction followed by a 
sustained response (longer than 24 months at diagnosis and 6–12 months at relapse) suggests to 
retreat with the same combination previously administered; in presence of short-term remission 
duration (less than 6 months) or progression during initial therapy, a different treatment regimen 
should be adopted.
54
 In presence of a biochemical relapse, that is ≥ 25% increase in the serum or 
urine protein and ≥ 0.5 mg/dL without symptoms, early treatment may keep the recurrence of the 
disease under control and delay clinical relapse. 





are the treatments of choice for relapsed patients. In the phase III APEX trial conducted in patients 
relapsed after at least 1 prior therapy, bortezomib alone showed to be superior to dexamethasone in 
terms of ORR (38% vs. 18%; p < 0.001), TTP (6.2 vs. 3.5 months; p < 0.001) and 1-year OS (80% 
vs. 60%; p = 0.003).
58
 An updated analysis showed an increase in ORR with bortezomib (43%) and 
confirmed the survival advantage with bortezomib over dexamethasone (29.8 vs. 23.2 months; 




Two phase III randomized trials, MM09 and MM010, enrolled relapsed/refractory patients after 1 to 
3 lines of prior therapy, and showed the superiority of RD over dexamethasone alone.
[29] and [40]
 RD 
resulted in higher ORR (60% vs. 20–24%) and longer median TTP (11 vs. 4.7 months) and median 
OS (29.6 vs. 20.6 months) compared with dexamethasone. These results led to the approval of 
lenalidomide for relapsed/refractory MM patients both in USA and Europe. 
When the treatment proves to be ineffective, a third drug (melphalan, cyclophosphamide or 
doxorubicin) may be added to enhance efficacy. In addition, bortezomib-based regimens should be 
preferred in relapsed patients with renal failure or previous deep-vein thrombosis.
60
 Patients 
previously treated with a thalidomide-containing regimen benefit from treatment with lenalidomide, 
although efficacy and survival may be lower.
61
 Because of the lack of neurotoxicity, lenalidomide is 
suggested in case of concomitant peripheral neuropathy.
60
 
The second generation proteasome inhibitor carfilzomib has shown a remarkable activity in 
relapsed/refractory MM patients, with a low rate of hematological AEs and the absence of 
neurotoxicity.
62
 The pivotal PX-171-003-A0 and PX-171-003-A1 studies tested single-agent 
carfilzomib in MM patients previously exposed to bortezomib and at least one IMiD.
[63] and [64]
 The 
ORR was 24% and the duration of therapy was 7.4 months. These data led to the FDA approval of 
carfilzomib as a single agent in relapsed/refractory MM patients after ≥ 2 lines of previous therapy, 
including bortezomib and one IMiDs. Carfilzomib was also tested in less heavily pre-treated and 
bortezomib-naïve relapsed/refractory MM, showing ORR of 42–52%.65 Recently, different doses of 
carfilzomib, lenalidomide and low-dose dexamethasone (CRd) were investigated in the relapse 
setting, resulting in an ORR of 75% at the highest dosage.
66
 The ongoing, phase III, randomized 
ASPIRE trial, is assessing the role of CRd in comparison with Rd in relapse/refractory MM 
patients. 
Pomalidomide, a new immunomodulatory drug, has recently shown high efficacy in patient's 
refractory to bortezomib and IMiDs. Clinical trials evaluating the efficacy of the dexamethasone 
and pomalidomide (dose, 2–4 mg) in patients relapsed and/or refractory to lenalidomide, 
bortezomib or both, reported a PR rate of 32–35% and a median PFS of 4.6–6.3 months. The 
addition of a third drug (cyclophosphamide) to the combination of prednisone and pomalidomide 
(PCP) increased at least PR rate (54%) and prolonged PFS (52% at 1 year).
67
 In a heavily pre-
treated population (median of 5 lines of previous therapy), the addition of clarithromycin to 
pomalidomide–dexamethasone induced a PR rate of 32% and a median PFS of 8.2 months.68 
A new generation of novel agents is currently under evaluation in relapsed/refractory MM patients: 
anti-CS1 monoclonal antibody (elotuzumab plus lenalidomide- or bortezomib–dexamethasone), 
oral proteasome inhibitor MLN9708, anti-CD138 antibody BT062 and histone deacetylase 
inhibitors vorinostat and panobinostat. Future trials will validate the role of these agents. 
9. Management of adverse events 
Prompt action with appropriate dose reductions is needed to manage adverse events, more frequent 
in elderly patients. 
9.1. Hematologic toxicity 
9.1.1. Anemia 
Anemia, typically due to bone marrow infiltration of MM cells, occurs in approximately two-thirds 
of newly-diagnosed MM patients.
69
 Erythropoiesis-stimulating agents (ESAs) are recommended for 
patients receiving chemotherapy to improve quality of life and reduce the risk of transfusion, 
particularly in patients with impaired renal function and those with low hemoglobin levels despite 
responding to therapy. ESAs should be started when hemoglobin level drops below 10 g/dl; in 
patients with impaired cardiac function or difficulty in performing daily-life activity, treatment can 
be started earlier. Hemoglobin level should be approximately 11–12 g/dl, as higher levels may 
increase the risk of cardiac events; when ESAs are administered in patients treated with multi-drug 





Neutropenia increases the risk of severe infection, a major cause of death in MM patients, and is 
generally related to chemotherapy. The risk of severe neutropenia (grade 3–4) during treatment is 
related to patient characteristics, baseline absolute neutrophil count (ANC), disease stage and type 
of chemotherapy administered (3-drug regimens including lenalidomide plus alkylators or 
doxorubicin are at high risk).
71
 Granulocyte-colony stimulating factor (G-CSF) can be used to 
manage severe neutropenia, both as primary prophylaxis or reactive treatment, thus allowing 
patients to stay on therapy for a longer period. Patients receiving high-risk therapies (expected 
grade 3–4 neutropenia rate > 50%) and those receiving intermediate- or low-risk regimens 
(expected grade 3–4 neutropenia rate < 50%) with additional risk factors, should be given G-CSF as 
primary prophylaxis. In patients receiving intermediate- or low-risk regimens with no other risk 
factor, G-CSF should be used only after occurrence of grade 3/4 neutropenia. If ANC rises to 
> 1000 cells/mL, therapy can be resumed and no dose modifications are needed. In case of 
persisting severe neutropenia despite G-CSF, therapy should be delayed until ANC recovery 




Alkylating and novel agents, especially bortezomib and lenalidomide, are frequently associated 
with thrombocytopenia.
72
 When platelet count falls below < 25,000/mm
3
 (grade 4 
thrombocytopenia) therapy should be withheld until thrombocytopenia resolves to at least grade 2 
(platelet count ≥ 50,000/mm3). Therapy could be then reintroduced with appropriate dose reductions 
of myelotoxic drugs. 
9.2. Non-hematologic toxicity 
9.2.1. Peripheral neuropathy 
Peripheral neuropathy (PN) is a common side effect observed in patients receiving thalidomide or 
bortezomib. It may frequently present as sensory neuropathy, neuropathic pain or, less frequently, 
as motor or autonomic neuropathy. Since PN is associated with the duration of drug exposure and 
no effective prophylactic measures are currently available to prevent it, dose reductions and 
temporary discontinuation are fundamental.
73
 Patients must be advised about signs and symptoms 
related to PN in order to promptly recognize and report them to physician. Different strategies have 
been recently assessed to decrease the rate of PN related to bortezomib. Phase III trials reported that 
the once-weekly schedule of bortezomib significantly decreased the rate of all grade PN and grade 
3–4 PN compared to the twice-weekly schedule, without affecting efficacy.[10], [13] and [44] Recently, a 
phase III study showed that the subcutaneous administration of bortezomib significantly reduced the 
rate of all grades PN and grade ≥ 3 PN in comparison with the intravenous administration, without 
negatively affecting responses and survival.
51
 When grade 1 PN without pain occurs, bortezomib 
dose should be decreased by one dose level or the schedule changed from twice- to once-weekly 
administration; if PN occurs during once-weekly bortezomib, the dose should be reduced by one 
dose level. In case of grade 2 PN, bortezomib dose should be decreased or changed to once-weekly 
administration; for patients receiving once-weekly bortezomib, dose reduction or temporary 
interruption should be considered. If neuropathy resolves to at least grade 1, bortezomib can be 
restarted at reduced dose and administered once-weekly. If grade 3–4 PN occurs treatment should 
be discontinued.
74
 For patients receiving thalidomide, when grade 2 PN occurs, halving thalidomide 
dose is an effective strategy; when grade ≥ 3 PN occurs, treatment with thalidomide should be 
discontinued and may be resumed if PN improves to grade 1 after appropriate dose reduction.
75
 
9.2.2. Venous thromboembolism 
Patients with MM have an increased risk of venous thromboembolism (VTE). Patient-related risks 
(age, obesity, inherited thrombophilia, history of VTE, immobilization, surgery, central venous 
catheter, comorbidity, ESAs treatment), myeloma-related risks (myeloma itself and hyperviscosity) 





 alone do not increase the risk of 
VTE. However, the addition of high-dose dexamethasone or doxorubicin to thalidomide or 
lenalidomide, or their administration in multi-drug chemotherapy, significantly increased the VTE 
risk.
[35], [42] and [78]
 In two randomized trials including patients receiving thalidomide- and 
lenalidomide-based regimens, aspirin and low-molecular weight heparin (LMWH) showed equal 
efficacy in reducing VTE. In low-risk patients (none or only one risk factor) receiving thalidomide 
or lenalidomide, prophylaxis with aspirin is recommended; in high-risk patients (≥ 2 risk factors) or 
in those treated with high-dose dexamethasone, doxorubicin or multi-drug chemotherapy, LMWH 
or full-dose warfarin should be used.
78
 
9.2.3. Renal failure 
Renal failure occurs in 20–40% of MM patients at diagnosis, due to damages related to free-light 
chains and concomitant factors, such as hyperuricaemia, hypercalcemia, dehydration and infections; 
nephrotoxic drugs may further impair renal function. Early intervention consists of reducing the 
load of free-light chains, removing precipitating factors. High-dose dexamethasone is able to 
rapidly reduce the load of light chains and to improve renal function.
79
 Pharmacokinetic of 
bortezomib and thalidomide are not affected by renal dysfunction. Bortezomib is well tolerated and 
highly active in patients with renal failure, being able to reverse renal impairment.
80
 Bortezomib 
plus dexamethasone is the treatment of choice in this setting.
81
 Lenalidomide is primarily excreted 
by kidneys, hence its dose must be adjusted based on creatinine clearance (CLcr).
82
 When CLcr 
level is between 30–60 mL/min, lenalidomide recommended dose is 10 mg per day; if CLcr level is 
below 30 mL/min, lenalidomide should be given at the dose of 15 mg every other day in patients 
not requiring dialysis or at the dose of 5 mg on the day of dialysis in patients under dialysis. 




Bone marrow infiltration by MM cells and myelotoxic chemotherapy increase the risk of severe 
infections (grade 3–4). In patients treated with novel agent-based regimens, the rate of severe 
infections varies between 7% and 14%.
[10], [16], [38] and [42]
 Bortezomib administration may lead to the 
reactivation of herpes zoster virus
79
; in patients receiving bortezomib, prophylaxis with acyclovir is 
recommended
84
. For patients treated with corticosteroids or myelotoxic drugs, or those with a 
higher risk of severe infections, routine antibiotic prophylaxis is suggested during the first cycles. 
Early recognition of fever or signs and symptoms of infection should lead to prompt administration 
of broad spectrum antibiotics. 
9.2.5. Bone disease 
Skeletal involvement due to MM cells infiltration occurs in 80% of MM patients, causing 
pathological fractures and pain, spinal cord compression and hypercalcemia.
1
 Biphosphonates, such 
as oral clodronic acid and intravenous pamidronic and zoledronic acid, are indicated to prevent 
bone disease. Zoledronic acid reduced skeletal-related events more than clodronic acid, with the 
advantage of longer PFS and OS.
[85] and [86]
 Both zoledronic and pamidronic acid are effective in 
decreasing skeletal-related events
87
; recently, no efficacy difference was seen with pamidronate 
administered at either 30 or 90 mg. In patients with mild to moderate renal impairment (30–
60 mL/min of creatinine clearance), dose reductions of zoledronic acid are recommended; in case of 
severe renal impairment (< 30 mL/min of creatinine clearance), pamidronic acid should be 
preferred.
88
 Therapy with bisphosphonates should last approximately 2 years to limit the risk of 
osteonecrosis of the jaw.
89
 Bone pain can be managed both pharmacologically and with local, 
fractioned radiotherapy. Analgesia should be firstly provided with non-opiod drugs (avoiding non-
steroidal antiinflammatory drugs); if pain persists, opiod drugs should be used. Lytic lesions 
causing bone instability may be treated with preventive orthopedic stabilization, vertebroplasty may 
be indicated to reduce pain due to vertebral fractures. 
10. Conclusions 
The combination of novel agents, bortezomib and IMiDs, with conventional chemotherapy has 
deeply improved outcome in elderly patients. The attainment of a profound and sustained 
cytoreduction proved to be a predictor of longer outcome. An induction regimen associated with a 
high probability of CR, and a continuous therapy with IMiDS or proteasome inhibitors prolong 
remission duration and improve outcome. A careful assessment of comorbidities, frailty and 
disability is essential to optimize treatment efficacy and reduce the frequency of adverse events. For 
very fit elderly patients, a sequential approach consisting of induction regimens incorporating novel 
agents, followed by reduced intensity ASCT and consolidation/maintenance is a valid therapeutic 
option. The standard of care for elderly patients not eligible for transplantation includes regimens 
with proteasome inhibitors, IMiDs, corticosteroids or alkylating agents in different combinations. In 
elderly unfit patients, a gentler approach with 2-drug regimen and a lower dose intensity should be 
adopted to avoid discontinuation and maximize treatment efficacy. In the relapse setting, the new 
proteasome inhibitor carfilzomib and the third generation IMiD pomalidomide, showed a great 
efficacy in patients relapsed/refractory to induction treatments. Newer agents, such as new oral 
proteasome inhibitors, monoclonal antibodies, and histone deacetylase inhibitors are currently under 
evaluation in clinical trials. 
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